10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30111% above fair value
$56.30+1.31 (+2.38%)
Close on Nov 17, 2026Market cap $7.34BP/E –Yield –
10x Genomics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
10x Genomics's operating income for the twelve months ending Sep 30, 2026 was -$72.20M. For fiscal 2025 it was -$60.99M. The highest annual figure on record is -$18.38M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.99M | – |
| FY2024 | Dec 31, 2024 | -$194.56M | – |
| FY2023 | Dec 31, 2023 | -$265.33M | – |
| FY2022 | Dec 31, 2022 | -$167.94M | – |
| FY2021 | Dec 31, 2021 | -$52.25M | – |
| FY2020 | Dec 31, 2020 | -$534.14M | – |
| FY2019 | Dec 31, 2019 | -$30.57M | – |
| FY2018 | Dec 31, 2018 | -$110.76M | – |
| FY2017 | Dec 31, 2017 | -$18.38M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$16.06M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.56M | -164.9% |
| Q1 FY2026 | Mar 31, 2026 | -$17.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.24M | – |
| Q2 FY2025 | Jun 30, 2025 | $30.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$41.49M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$61.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$55.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$94.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$63.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$40.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$41.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$409.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$65.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$39.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.08M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.36M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.04M | – |
| Q4 FY2018 | Dec 31, 2018 | -$74.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.93M | – |
See a number that looks wrong?